CN102448306B - 用于预防和/或治疗中枢神经系统退行性紊乱的方法 - Google Patents

用于预防和/或治疗中枢神经系统退行性紊乱的方法 Download PDF

Info

Publication number
CN102448306B
CN102448306B CN201080024142.1A CN201080024142A CN102448306B CN 102448306 B CN102448306 B CN 102448306B CN 201080024142 A CN201080024142 A CN 201080024142A CN 102448306 B CN102448306 B CN 102448306B
Authority
CN
China
Prior art keywords
therapeutic agent
compound
piperidine
diol
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080024142.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102448306A (zh
Inventor
R·博伊德
G·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of CN102448306A publication Critical patent/CN102448306A/zh
Application granted granted Critical
Publication of CN102448306B publication Critical patent/CN102448306B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080024142.1A 2009-04-09 2010-04-09 用于预防和/或治疗中枢神经系统退行性紊乱的方法 Expired - Fee Related CN102448306B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16810109P 2009-04-09 2009-04-09
US61/168,101 2009-04-09
PCT/US2010/030470 WO2010118282A1 (en) 2009-04-09 2010-04-09 Methods for preventing and/or treating degenerative disorders of the central nervous system

Publications (2)

Publication Number Publication Date
CN102448306A CN102448306A (zh) 2012-05-09
CN102448306B true CN102448306B (zh) 2014-07-02

Family

ID=42934882

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080024142.1A Expired - Fee Related CN102448306B (zh) 2009-04-09 2010-04-09 用于预防和/或治疗中枢神经系统退行性紊乱的方法

Country Status (11)

Country Link
US (1) US8304429B2 (https=)
EP (1) EP2416655B1 (https=)
JP (1) JP5634498B2 (https=)
CN (1) CN102448306B (https=)
AU (1) AU2010233187B2 (https=)
BR (1) BRPI1015472A2 (https=)
CA (1) CA2758187C (https=)
ES (1) ES2505243T3 (https=)
IL (1) IL215584A (https=)
NZ (1) NZ595630A (https=)
WO (1) WO2010118282A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1010517A2 (pt) * 2009-04-09 2017-01-31 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal
SI2995306T1 (sl) * 2009-10-19 2019-04-30 Amicus Therapeutics, Inc. Novi sestavki za preprečevanje in/ali zdravljenje motenj lizosomskega shranjevanja
KR101880411B1 (ko) 2009-10-19 2018-07-19 아미쿠스 세라퓨틱스, 인코포레이티드 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물
CA2817960C (en) 2010-11-17 2020-06-09 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
WO2013070981A2 (en) * 2011-11-08 2013-05-16 University Of Central Florida Research Foundation, Inc. Treating er stress related disorders by stabilizing intracellular calcium homeostasis
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
US9796680B2 (en) 2013-12-23 2017-10-24 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN110177572A (zh) * 2016-09-12 2019-08-27 史蒂文·霍夫曼 用于治疗痴呆的组合物
BR112018014281A2 (pt) * 2016-11-15 2018-12-18 H Lundbeck As agentes, usos e métodos para o tratamento da sinucleinopatia
SG11202006528XA (en) 2018-01-12 2020-08-28 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN120310791A (zh) 2018-01-12 2025-07-15 百时美施贵宝公司 靶向α-突触核蛋白的反义寡核苷酸及其用途
CN119606967B (zh) * 2024-12-13 2025-09-05 合肥工业大学 氯雷他定在制备用于预防和治疗血管钙化药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024391A1 (en) * 1994-03-09 1995-09-14 Novo Nordisk A/S Piperidines and pyrrolidines
US6670625B1 (en) * 2002-06-18 2003-12-30 Ge Medical Systems Global Technology Company, Llc Method and apparatus for correcting multipole aberrations of an electron beam in an EBT scanner
WO2004037233A2 (en) * 2002-10-28 2004-05-06 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
WO2007150064A2 (en) * 2006-06-23 2007-12-27 Amicus Therapeutics, Inc. METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060079533A1 (en) * 2001-03-23 2006-04-13 Nieman James A Methods of treating alzheimer's disease
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
AU2006254796B2 (en) * 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
US20080009156A1 (en) 2006-07-10 2008-01-10 Malin Glen K System and method for bonding coaxial cable
BRPI1010517A2 (pt) * 2009-04-09 2017-01-31 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024391A1 (en) * 1994-03-09 1995-09-14 Novo Nordisk A/S Piperidines and pyrrolidines
US6670625B1 (en) * 2002-06-18 2003-12-30 Ge Medical Systems Global Technology Company, Llc Method and apparatus for correcting multipole aberrations of an electron beam in an EBT scanner
WO2004037233A2 (en) * 2002-10-28 2004-05-06 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
WO2007150064A2 (en) * 2006-06-23 2007-12-27 Amicus Therapeutics, Inc. METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE

Also Published As

Publication number Publication date
EP2416655A4 (en) 2012-09-05
AU2010233187A1 (en) 2011-11-03
EP2416655A1 (en) 2012-02-15
IL215584A0 (en) 2011-12-29
BRPI1015472A2 (pt) 2015-11-24
JP5634498B2 (ja) 2014-12-03
JP2012523430A (ja) 2012-10-04
ES2505243T3 (es) 2014-10-09
US20100261753A1 (en) 2010-10-14
IL215584A (en) 2016-11-30
EP2416655B1 (en) 2014-06-25
AU2010233187B2 (en) 2015-10-08
NZ595630A (en) 2013-04-26
CA2758187A1 (en) 2010-10-14
HK1168005A1 (zh) 2012-12-21
US8304429B2 (en) 2012-11-06
CA2758187C (en) 2017-03-07
CN102448306A (zh) 2012-05-09
WO2010118282A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
CN102448306B (zh) 用于预防和/或治疗中枢神经系统退行性紊乱的方法
RU2581058C2 (ru) Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
JP5645918B2 (ja) リソソーム蓄積障害の予防および／または治療方法
HK1168005B (en) Methods for preventing and/or treating degenerative disorders of the central nervous system
HK1235628A (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
HK1235628A1 (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
HK1235628B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
HK1175074A (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1168005

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1168005

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140702